Mason Carrico
Stock Analyst at Stephens & Co.
(4.09)
# 523
Out of 5,113 analysts
77
Total ratings
51.47%
Success rate
14.55%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $241.58 | -2.72% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $2.58 | -22.48% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.05 | +1.27% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $12.81 | -14.13% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $37.85 | +77.01% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $150.28 | -30.13% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $22.38 | -37.44% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $20.42 | +95.89% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $119.98 | -4.15% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $42.27 | +6.46% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $114.75 | -52.07% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $5.27 | +13.85% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $19.14 | -11.18% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $65.92 | -21.12% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.87 | +240.72% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $42.24 | -2.94% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $241.58
Upside: -2.72%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $2.58
Upside: -22.48%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.05
Upside: +1.27%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $12.81
Upside: -14.13%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $37.85
Upside: +77.01%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $150.28
Upside: -30.13%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $22.38
Upside: -37.44%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $20.42
Upside: +95.89%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $119.98
Upside: -4.15%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $42.27
Upside: +6.46%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $114.75
Upside: -52.07%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.27
Upside: +13.85%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $19.14
Upside: -11.18%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $65.92
Upside: -21.12%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.87
Upside: +240.72%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $42.24
Upside: -2.94%